Overview
Aptar Q3 sales increase 6%, beating analyst expectations
Adjusted EPS for Q3 beats consensus, reflecting strong operational performance
Company returned $70 mln to shareholders via buybacks and dividends
Outlook
Aptar expects Q4 2025 adjusted EPS between $1.20 and $1.28
Company anticipates strong Pharma segment growth, driven by GLP-1 and biologics demand
Aptar foresees less favorable sales mix due to lower emergency-use system sales
Result Drivers
PHARMA GROWTH - Strong product volume growth in Pharma, especially in injectables, drove sales increase
BEAUTY SEGMENT - Beauty segment sales increased due to currency and acquisitions, but core sales remained flat
CLOSURES CHALLENGES - Closures segment faced lower tooling sales and resin pricing, affecting core sales
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $961 mln | $953.50 mln (6 Analysts) |
Q3 Adjusted EPS | Beat | $1.62 | $1.56 (7 Analysts) |
Q3 EPS | $1.92 | ||
Q3 Net Income | $128 mln | ||
Q3 Adjusted EBITDA | Beat | $223 mln | $212.98 mln (6 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the non-paper containers & packaging peer group is "buy"
Wall Street's median 12-month price target for Aptargroup Inc is $167.00, about 25.5% above its October 30 closing price of $124.36
Press Release: ID:nBw4fn8Ta
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)